23
Oct
2026
Creating PROTACs and RIPTACs: Tim Shannon on The Long Run
Tim Shannon is today’s guest on The Long Run. Tim is a general partner at Canaan Partners. He was a pulmonary and critical care physician in the early part of his career, before moving over to R&D leadership in industry, and then eventually into venture capital investing. Tim got started as a VC during the Great Financial Crisis. That may... Read More
15
Oct
2026
BMS Hits IPF Goal, Iambic and City IPO & AZ Invests in Insitro
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Oct
2026
AAV Gene Therapy: What It Will Take To Get Through the Wilderness
When Luke first asked for my perspective on the state of AAV gene therapy over the summer, he asked me “Will AAV ever deliver on its early promise? Be safe? Be commercially successful?”. After ruminating for a while, I settled on the Stockdale paradox (as chronicled in Jim Collins’ Good to Great) as the best description of where we stand.... Read More
13
Oct
2026
Biotech IPO Scorecard: Triple the Action in 2026
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Oct
2026
Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Oct
2026
Touch, Pain, and the Edge of Neuroscience: Ardem Patapoutian on The Long Run
Ardem Patapoutian is today’s guest on The Long Run. Ardem is a professor of neuroscience at Scripps Research in San Diego, and an investigator with Howard Hughes Medical Institute. His lab is focused on ion channels on the surface of cells that sense mechanical force, and how those signals are translated into our sense of touch, pain, and other basic... Read More
6
Oct
2026
Arboretum Gets $30M to Expand Molecular Dx for Healthcare & Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Sep
2026
Enveda Cashes In, Otsuka Hits ALS Goal, & Viking Braces for GLP-1 Battle
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Sep
2026
Long-Lasting Antibodies for Immune Diseases: Cameron Turtle on The Long Run
Cameron Turtle is today’s guest on The Long Run. Cameron is the CEO of Waltham, Mass.-based Spyre Therapeutics. The company is developing antibody drug candidates that are engineered to be longer-lasting than today’s drugs for immune disorders. This means patients could take fewer injections and the drugs should stay stable in the bloodstream to keep the disease under control longer.... Read More
17
Sep
2026
Scholar Rock Gets FDA OK, Reverse Mergers Continue & Novartis Bets on Brain Delivery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Sep
2026
Novartis’ Rough Week, AstraZeneca’s Better Week, & GV Life Sciences Leader Moves On
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Sep
2026
Drugs That Go Where None Could Before: Mathai Mammen on The Long Run
Mathai Mammen is today’s guest on The Long Run. Mathai is the CEO of Cambridge, Mass.-based Parabilis Medicines. The company has a platform for making drugs that hit elusive biological targets known as drivers of disease. Parabilis attacks them with alpha-helical peptide drug candidates that can get inside cells and bind with relatively flat and smooth surfaces of proteins. It... Read More
3
Sep
2026
Alumis & BioNTech Stumble, Lilly Buys Merida, & Takeda’s Latest FDA Approval
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Sep
2026
IYKYK: Leave the Vortex, Take the Influence
It’s not just your kids who aspire to become influencers. Attracting attention –- often through provocative content delivered through social media at high volume –- can seem increasingly like a business imperative, as the a16z co-founders have described (here, here) and, in the case of Andreessen, unhesitatingly embraced. The Attention Imperative But they’re not alone; many physicians, researchers, and policy... Read More
27
Aug
2026
RevMed’s Watershed, Roivant Goes Commercial, & Roche’s Blood Test for Alzheimer’s
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Aug
2026
A Vaccine for Epstein-Barr Virus: Gary Nabel on The Long Run
Gary Nabel is today’s guest on The Long Run. Gary is the CEO of Weston, Mass.-based ModeX Therapeutics. The company has a platform for making multi-specific biologics into vaccines and cancer treatments. ModeX was founded in 2020, building on work that started at Sanofi when Nabel was the chief scientific officer there. The initial application of this technology, currently in... Read More
20
Aug
2026
Moderna’s Home Run, Amylyx Bounces Back, & Enveda Advances Workout-in-a-Pill
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Aug
2026
9 Young Scientists to Watch: the Timmerman Traverse Fellows at Damon Runyon
Our community’s steadfast support of science is more important than ever given the tenuous state of federal research funding. Teams of biotech executives and investors have raised $3.9 million for high-risk/high-reward cancer research since 2024 as part of the Timmerman Traverse for Damon Runyon Cancer Research Foundation. The Traverse has created fun outdoor experiences and lasting friendships. We’ve hit the... Read More
17
Aug
2026
Harell Data Debuts With $15M To Change Incentives, Speed Up AI Drug Discovery
The Protein Data Bank was the unsung hero that made AlphaFold possible. For decades, the structural biologists, biochemists and others who put carefully curated protein structures in the public domain laid down the conditions for AI to eventually do something useful – predicting protein structures in this case. Those scientists never got a nickel. This is just one of many... Read More
16
Aug
2026
The Narrative Machine: What AI Really Adds to Personal Health Data
For years, the Quantified Self movement had a stubborn problem: our devices became increasingly good at generating data but remained remarkably poor at telling us what any of it meant. Generative AI now dangles a tantalizing possibility: that it can tease genuinely useful personal insights from all those measurements and hand them back to us in a form we can... Read More